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Neonatal  exposure  to isoﬂavones  improved  bone  health  in  thereafter  in  previous  animal
studies.  However,  since  isoﬂavones  possess  hormonal  activity,  it may  interfere  with  repro-
ductive  development.  In  the present  study,  we  assessed  the  safety  and  efﬁciency  of  perinatal
or peripubertal  exposure  to  daidzein  on  bone  and  reproductive  organ  development  at  early
adulthood  in  rats. Sprague-Dawley  pregnant  rats  (n = 18) were  divided  into  3 groups:  (1)
dams and  their  offspring  were  fed  the  control  diet. (2)  Dams  were  fed  the daidzein  diet
(0.5 g  daidzein/kg  diet)  during  pregnancy  and  then  the  control  diet  at postnatal  day  13  and
their offspring  were  fed  the  control  diet. (3) Dams  and  their  offspring  were  fed the  daidzein
diet through  the  experiment.  While  perinatal  exposure  to daidzein  did  not  confer  a posi-
tive  effect  on bone  mineral  density  on  postnatal  day  35,  peripubertal  exposure  to  daidzein
protected  against  a decline  in bone  mineral  density.  Meanwhile,  exposure  to  daidzein  dur-
ing  the  perinatal  or peripubertal  period  did not  affect  reproductive  organ  weights  at early
adulthood  in rats. Further  investigations  should  assess  the  mechanisms  underlying  these
responses  of bone  metabolism  to daidzein,  as well  as  the  safety  of  daidzein  exposure  during
the perinatal  period  and  throughout  life.
© 2015  The  Authors.  Published  by  Elsevier  Ireland  Ltd. This  is  an  open  access  article  under
Y-NC-Nthe  CC  B
. IntroductionThe recent growing interest in health and diet has led
o an increased focus on soy foods and their functional
omponents, such as isoﬂavones. Soy isoﬂavones have a
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structure similar to that of estrogen and have weak estro-
genic activity [1]. Therefore, isoﬂavones have been used
by some postmenopausal women  as a natural alterna-
tive to estrogen replacement therapy for prevention of
postmenopausal osteoporosis [2]. Equol is a metabolite of
daidzein. Equol is formed by microbiota in the intestine
and it binds to estrogen receptors (ERs) and induces tran-
scription more strongly than soy isoﬂavones [3]. Lampe [4]
suggested that the clinical effectiveness of soy isoﬂavones
is due to their ability to produce equol.Estrogen plays a critical role in the skeletal development
of female and male mammals throughout life [5]. However,
the effects of isoﬂavone exposure during early life on bone
development have not been extensively studied. Injecting
cess article under the CC BY-NC-ND license (http://creativecommons.org/
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pregnant mice with diethylstilbestrol during pregnancy
results in positive, long-lasting effects on the skeleton of
female offspring [5]. This ﬁnding suggests that in utero
exposure to estrogen can result in programming of bone
cells. Moreover, short-term exposure to estrogen or com-
pounds with estrogen-like activity during early stages of
development has positive effects on bone health in adult-
hood in mice [6]. Female offspring of mice exposed to soy
isoﬂavones have a higher bone mineral density (BMD) com-
pared with control group and improved femur structure
at 4 months of age, the time when maximal bone mass
is established in CD-1 mice [7–9]. However, Kaludjerovic
and Ward [10] reported that short-term neonatal exposure
to isoﬂavones provides protection against deterioration of
bone tissue in female mice, but not in male mice, after a
decline in endogenous sex steroid production. We previ-
ously reported that consumption of a diet with 0.08% (w/w)
isoﬂavones stimulates bone formation in immature male
mice and exerts the opposite effect in female mice [11].
These results suggest that daidzein has a speciﬁc, sexu-
ally dimorphic effect on bone formation and BMD  during
growth periods.
Consumption of soy isoﬂavone supplements during
early life is frequently associated with beneﬁcial effects on
bone development in mice [7–9]. However, there is concern
regarding isoﬂavones as endocrine-disrupting chemicals
because of their estrogenic activity [12,13]. Pregnancy and
lactation are hormone-sensitive and important periods in
the development of reproductive capacity of offspring.
Therefore, the fetus or nursing offspring may  be more
affected by estrogen or food components with potential
hormonal activity than adults. Several studies have shown
that perinatal exposure to isoﬂavones in rodents induces
adverse reproductive effects on the offspring, such as a
change in reproductive organ weight and serum hormone
levels in mice and rats [12–14].
We  previously reported that isoﬂavones were present in
the milk of dams that were exposed to isoﬂavones in rats
[15]. The maternal–fetal intrauterine transfer of isoﬂavones
in rats fed a diet supplemented with isoﬂavones elicits high
serum isoﬂavone levels in rat pups. These high levels are
maintained throughout the suckling period by the passage
of isoﬂavones into maternal milk [15,16]. Therefore, human
infants can be exposed to elevated levels of isoﬂavones
throughout nursing if the mother is consuming a diet that
is abundant in soy foods or supplements [17]. However,
few studies have assessed the transfer of isoﬂavone and its
metabolite equol from mothers to the nursing offspring.
Therefore, the objective of the present study was to assess
the safety and efﬁciency of perinatal or peripubertal expo-
sure to daidzein on bone development and on reproductive
organs at early adulthood in rats.
2. Materials and methods
2.1. AnimalsFemale Sprague-Dawley rats at day 5 of gestation
were purchased from Charles River Laboratories Japan,
Inc. (Yokohama, Japan). Rats were housed individually in
clear plastic cages with wire-mesh covers and paper chipFig. 1. Experimental design. PND: postnatal day
bedding (ALPHA-DriTM, Shepherd Specialty Papers, Inc.,
Richland, MI). The weaned offspring were housed individ-
ually in stainless-steel cages. Rats were maintained in a
temperature- and humidity-controlled room (23 ± 1 ◦C and
60% ± 5% relative humidity) with a 12-h light–dark cycle.
The offspring were kept in the same groups as their respec-
tive dams. Dams were pair-fed their respective diet and
offspring were pair-fed their respective diets among males
or females. This experiment complied with the guidelines
of the Standards Relating to the Care and Management of
Experimental Animals and Relief of Pain of the Japanese
government (Notice No. 88 of the Ministry of the Environ-
ment, 2006).
2.2. Diets and chemicals
Pregnant rats were fed diet mixtures containing
daidzein at dose levels of 0 or 0.5 g/kg. These diets were
based on the modiﬁed AIN-93G diet with replacement of
corn oil for soybean oil [18]. All ingredients were pur-
chased from Oriental Yeast Co., Ltd. (Tokyo, Japan). Puriﬁed
daidzein (>98% purity) and equol were purchased from LC
Laboratories Co., Ltd. (Woburn, MA).
2.3. Experimental design
The experimental design is shown in Fig. 1. Pregnant rats
at day 5 of gestation (n = 18) of random body weights were
divided into three groups of six rats each: dams and their
offspring were fed the control diet (Control); dams were
fed the daidzein diet (0.5 g/kg diet) during pregnancy and
then the control diet at postnatal day (PND) 13 and their
offspring were fed the control diet (Dz-S); and dams and
their offspring were fed the daidzein diet (Dz-L) through
the experiment. Accordingly, pups in the Dz-S group were
exposed to daidzein only through the placenta and the milk
from the dams. The day of birth was  designated as PND 1.
On PND 1, the number of pups was adjusted to eight (4
males and 4 females) for each dam. Litter size, birth weight,
and the sex ratio were measured as pregnancy outcomes.
Pups were weaned on PND 22, and offspring were housed
in individual cages. From PNDs 22 to 77, offspring were
logy Rep
w
s
e
2
d
r
p
w
w
a
f
(
2
t
a
[
b
u
a
2
a
s
J
t
c
r
S
m
T
2
o
s
[
u
(
(
w
d
(
N
K
p
4
r
2
w
I
s
lY. Tousen et al. / Toxico
eighed weekly and food intake was measured daily. Off-
pring (1 female and 1 male per litter) were anesthetized by
xposure to diethyl ether (Wako, Osaka, Japan) on PNDs 14,
2, 35, and 77, and dams were anesthetized by exposure to
iethyl ether on PND 22. After laparotomy, the stomach was
emoved on PND 14. Whole blood was collected by cardiac
uncture, and the testes, seminal vesicles, ovaries, and uteri
ere removed and weighted on PNDs 22, 35, and 77. Serum
as separated by centrifugation at 3000 rpm for 20 min
nd frozen at −80 ◦C. For measurement of BMD, the right
emur was removed and stored in 70%/30% ethanol/water
Sigma–Aldrich Japan, Tokyo, Japan).
.4. Pup development
Hormonal imbalances in male or female pups due to
he diet treatments were determined by comparing their
nogenital distance (AGD) measurements with those of rats
12]. AGD, which is the length of the perineum from the
ase of the genital tubercle to the proximal edge of the anus
nder natural extension without stretching, was measured
t PNDs 14 and 22.
.5. Quantiﬁcation of BMD  and bone metabolism
Femoral BMD  was measured by dual-energy X-ray
bsorptiometry using a specialized software program for
mall animals (Model DCS-600EX-R III, Aloka, Ltd., Tokyo,
apan). BMD  was calculated using the bone mineral con-
ent of the measured area. Intra-assay and inter-assay
oefﬁcients of variation were less than 1.0% and 4.8%,
espectively. The detection limit of BMD  is 15 mg/cm2.
erum osteocalcin levels were measured with a com-
ercial kit, the Rat Osteocalcin EIA Kit (Biomedical
echnologies, Inc., Stoughton, MA).
.6. Serum daidzein and equol concentrations in
ffspring and the stomach contents of pups
Serum daidzein and equol concentrations were mea-
ured by the methods reported by Gamache and Acworth
19]. An aliquot of the pretreated sample solution was
sed for high-performance liquid chromatography (HPLC)
Shimadzu LC10AD) with an electrochemical detector
Coulochem III, ESA Laboratories Inc., Chelmsford, MA)  that
as equipped with analytical cells (detector 1, 300 mV;
etector 2, 600 mV)  (ESA) and a guard cell (650 mV)
ESA). The HPLC conditions were as follows: column,
ova-Pac C18 (Waters, 3.9 mm × 150 mm;  Nihon Waters
.K., Tokyo, Japan); column temperature, 40 ◦C; mobile
hase, 50/35/15% (v/v/v) 50 mM sodium acetate (pH
.8):methanol:acetonitrile (Wako, Osaka, Japan); and ﬂow
ate, 0.65 ml/min.
.7. Statistical analysis
Data are expressed as means ± SEM. All statistical tests
ere conducted with SPSS, version 15.0 (SPSS Inc., Chicago,
L). Signiﬁcance of differences in BMD  was determined by
ingle-factor analysis of covariance and Fisher’s protected
east signiﬁcant difference tests. Body weight was  usedorts 2 (2015) 429–436 431
as a covariate in the analysis of BMD  to adjust for pos-
sible confounding. Body weight, AGD, reproductive organ
weight, and serum isoﬂavone and osteocalcin concentra-
tions were analyzed using analysis of variance (ANOVA).
Differences between treatment groups were assessed by
Tukey’s test. Differences were considered signiﬁcant at
p < 0.05.
3. Results
3.1. Pregnancy outcomes
There was  no difference in the number of pups per litter
among the groups (Control = 13.3 ± 1.0; Dz-S = 12.2 ± 1.4,
and Dz-L; 12.3 ± 0.9). There were also no differences in the
number of males and females per litter (m,  f: Control = 6.5,
6.8; Dz-S = 6.7, 5.5; and Dz-L = 7.0, 5.3) and birth weight
among the groups (Control = 7.0 ± 0.3 g; Dz-S = 7.4 ± 0.2 g;
Dz-L = 7.5 ± 0.2 g).
3.2. Body weight, food intake, AGD, and sex organ weight
The mean body weight for males on PND 1 (day of birth)
and PND 22 (weaning day) was  not signiﬁcantly differ-
ent among the groups (Table 1). The mean body weight
for males on PND 35 was  signiﬁcantly higher in the Dz-L
group than in the Control and Dz-S groups, but there was
no signiﬁcant difference among groups on PND 77. There
was no difference in total weight gained among the groups
(Table 1). There was  no difference in food intake in dams
and offspring among the groups (data not shown). There
were no signiﬁcant differences in mean body weight and
the total weight gained in females at any of the time points
among the groups (Table 1).
Table 2 shows AGD and sex organ weight. The AGD of
male and female offspring on PNDs 14 and 22 was not dif-
ferent among the groups. On PNDs 22, 35 and 77, treatment
with daidzein had no effect on the mean weight of testes
and seminal vesicles. The weight of the ovaries and uterus
in female offspring on PNDs 22, 35, and 77 was  not altered
by daidzein exposure to the dams or offspring.
3.3. BMD  of the femur
On PND 22, there was  no difference in femur BMD  in
male and female rats among the groups (Fig. 2A and B). On
PND 35, femur BMD  in male and female rats in the Dz-S
group was  signiﬁcantly lower than that in the Control and
Dz-L groups (Fig. 2C and D). On PND 77, femur BMD  in male
rats in the Dz-S group was  signiﬁcantly lower than that in
the Control and Dz-L groups (Fig. 2E). However, femur BMD
in female rats was not different among the groups on PND
77 (Fig. 2F).
3.4. Serum osteocalcin concentrations
Table 3 shows serum osteocalcin concentrations, which
are a biochemical marker of bone formation. In male rats,
mean serum osteocalcin concentrations on PND 22 were
signiﬁcantly lower in the Dz-S and Dz-L groups (1.48 ± 0.08
and 1.51 ± 0.08 ng/ml, respectively) than in the Control
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Table 1
Body weight and total weight gain of offspring on PNDs 1, 22, 35, and 77.
Group Control Daidzein Short Daidzein Long
Male
Body weight (g)
PND 1 7.32 ± 0.36 7.60 ± 0.29 7.90 ± 0.32
PND  22 67.5 ± 1.2 63.6 ± 1.6 63.1 ± 1.7
PND  35 151.4 ± 1.7b 148.2 ± 1.0b 158.6 ± 2.0a
PND 77 433.0 ± 6.7 430.8 ± 11.8 439.8 ± 14.8
Total  weight gain (g) 425.7 ± 6.5 423.2 ± 12.0 431.9 ± 15.0
Female
Body weight (g)
PND 1 3.56 ± 0.40 3.30 ± 0.51 3.03 ± 0.26
PND  22 65.0 ± 0.3 61.0 ± 1.3 61.0 ± 1.9
PND  35 130.7 ± 2.2 127.5 ± 3.8 135.5 ± 5.4
PND  77 243.3 ± 4.3 242.6 ± 7.5 233.0 ± 17.0
Total  weight gain (g) 239.8 ± 4.4 239.2 ± 7.3 230.0 ± 6.8
All values are means ± SE (n = 6). Values that do not share the same superscript letters are signiﬁcantly different from each other (p < 0.05). Data were
analyzed using one-way ANOVA. Differences between the groups were assessed by Tukey’s test.
Dams and their offspring fed the control diet (Control); dams fed the daidzein diet (0.5 g daidzein/kg diet) during pregnancy then the Control diet at
postnatal day (PND) 13 and their offspring fed the Control diet (Dz-S); and dams and their offspring fed the daidzein diet (Dz-L).
PND: postnatal day.
Table 2
Anogenital distance and sex organ weight of offspring on PNDs 14, 22, 35, and 77.
Group Control Daidzein Short Daidzein Long
Male
Anogenital distance (mm)
PND 14 3.72 ± 0.09 3.96 ± 0.18 3.77 ± 0.11
PND  22 3.14 ± 0.10 3.14 ± 0.11 3.21 ± 0.13
Testis  weight (mg)
PND 22 277 ± 10 264 ± 14 262 ± 14
PND  35 1304 ± 42 1346 ± 40 1277 ± 43
PND  77 3353 ± 27 3319 ± 44 3233 ± 75
Seminal vesicle (mg)
PND 22 43 ± 2 45 ± 2 44 ± 2
PND  35 161 ± 12 149 ± 9 169 ± 25
PND  77 922 ± 49 922 ± 37 967 ± 55
Female
Anogenital distance (mm)
PND 14 2.61 ± 0.10 2.89 ± 0.11 2.72 ± 0.03
PND  22 2.01 ± 0.04 2.15 ± 0.08 2.12 ± 0.09
Ovaries + uterus (mg)
PND 22 65 ± 3 67 ± 5 68 ± 3
PND  35 210 ± 33 167 ± 21 233 ± 27
PND  77 515 ± 48 546 ± 41 541 ± 54
All values are means ± SE (n = 6). Data were analyzed using one-way ANOVA. Differences between the groups were assessed by Tukey’s test (p < 0.05).
Dams  and their offspring fed the control diet (Control); dams fed the daidzein diet (0.5 g daidzein/kg diet) during pregnancy then the Control diet at
postnatal day (PND) 13 and their offspring fed the Control diet (Dz-S); and dams and their offspring fed the daidzein diet (Dz-L).
PND: postnatal day.
Table 3
Serum osteocalcin concentrations in rat offspring on PNDs 22, 35, and 77.
Group Control Daidzein Short Daidzein Long
Osteocalcin (ng/ml)
Male
PND 22 1.91 ± 0.12a 1.48 ± 0.08b 1.51 ± 0.08b
PND 35 4.08 ± 0.22ab 3.34 ± 0.30b 4.45 ± 0.20a
PND 77 5.04 ± 0.33 4.23 ± 0.17 4.84 ± 0.22
Female
PND 22 1.64 ± 0.04 1.62 ± 0.06 1.63 ± 0.05
PND  35 3.95 ± 0.10a 3.37 ± 0.09b 3.67 ± 0.06ab
PND 77 4.23 ± 0.11 4.16 ± 0.14 4.11 ± 0.13
All values are means ± SE (n = 6). Values that do not share the same superscript letters are signiﬁcantly different from each other (p < 0.05). Data were
analyzed using one-way ANOVA. Differences between the groups were assessed by Tukey’s test.
Control; the group fed the control diet, Daidzein Short; the group fed the daidzein diet (0.5 g daidzein/kg diet) during both pregnancy and lactation periods,
Daidzein Long; the group fed the daidzein diet (0.5 g daidzein/kg diet) during pregnancy, lactation and postweaning periods.
PND:  postnatal day.
Y. Tousen et al. / Toxicology Reports 2 (2015) 429–436 433
Fig. 2. Bone mineral density of the right femur in offspring of dams that were fed the control diet or the diet containing 0.5 g daidzein/kg during pregnancy
and  lactation and/or the post-weaning period. Data are shown for PNDs 22, 35, and 77. All values are means ± SEM (n = 6). Values that do not share the
same  superscript letters are signiﬁcantly different from each other (p < 0.05). Signiﬁcant differences in BMD  were determined by one-factor ANCOVA and
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roup (1.91 ± 0.12 ng/ml). On PND 35, the mean serum
steocalcin concentration in the Dz-S group was signiﬁ-
antly lower than that in the Dz-L group (4.45 ± 0.20 ng/ml)
n male rats. On PND 77, there was no difference in serum
steocalcin concentrations in male rats among the groups.control diet; Dz-S group: rats were fed a daidzein diet (0.5 g daidzein/kg
 (0.5 g daidzein/kg diet) during pregnancy, lactation, and post-weaning.
In female rats, mean serum osteocalcin concen-
trations were signiﬁcantly lower in the Dz-S group
(3.37 ± 0.09 ng/ml, p = 0.001) and tended to be lower
(p = 0.085) in the Dz-L group (3.67 ± 0.06 ng/ml) than in
the Control group (3.95 ± 0.10 ng/ml) on PND 35 (Table 3).
logy Rep434 Y. Tousen et al. / Toxico
There was no difference in mean serum osteocalcin con-
centrations in female rats among the groups on PNDs 22
and 77.
3.5. Stomach content and serum daidzein and equol
concentrations
Serum daidzein and equol concentrations were
detected in dams in the Dz-L group (4.30 ± 0.45 and
5.71 ± 1.26 mol/L, respectively). Stomach contents of
daidzein and equol in each offspring were measured and
combined the values from male and female. Daidzein
(11.86 ± 1.28 and 15.12 ± 5.32 nmol/g, respectively) and
equol (1.29 ± 0.29 and 3.37 ± 1.14 nmol/g, respectively)
were detected in the stomach contents of the suckling
pups of dams in the Dz-S and Dz-L groups (Fig. 3). Serum
daidzein and equol concentrations were observed in the
offspring on PNDs 22 (2.03 ± 0.40 and 1.58 ± 0.18 mol/L,
respectively), 35 (4.23 ± 0.91 and 4.40 ± 1.08 mol/L,
respectively), and 77 (1.17 ± 0.33 and 4.31 ± 0.76 mol/L,
respectively) in the Dz-L group.
4. Discussion
This study showed that perinatal exposure to daidzein
inhibited an increase in BMD  and serum osteocalcin con-
centrations in male and female rats on PND 35. However,
peripubertal exposure to daidzein protected against the
decline of these bone parameters in male and female rats
on PND 35. On PND 77, femur BMD  in male rats that were
exposed to daidzein perinatally was lower than that in con-
trol rats or those with peripubertal exposure to daidzein.
However, femur BMD  in female rats was not different
among the groups. These results suggest that the effects of
daidzein on bone metabolism during development depend
on the timing of exposure and sex. However, perinatal or
peripubertal exposure to daidzein did not affect develop-
ment of reproductive organs by early adulthood in rats.
On PND 35, femur BMD  in male and female rats in
the Dz-S group was signiﬁcantly lower than that in the
Control and Dz-L groups (Fig. 2C and D). Similarly, serum
osteocalcin concentrations, a biochemical marker of bone
formation, tended to be lower in male and female rats in
the Dz-S group than in the Control and Dz-L groups on
PND 35 (Table 3). On PND 77 in male rats, femur BMD  in
the Dz-S group was signiﬁcantly lower than that in the
Control and Dz-L groups (Fig. 2E), but female BMD  was
not different among the groups (Fig. 2F). Our results sug-
gest that perinatal and postnatal daidzein exposure show
different effects on bone metabolism. Mardon et al. [20]
reported that rats with perinatal or lifelong exposure to
an isoﬂavone-rich diet had increased femoral and meta-
physeal BMD  at 24 months, but there was no signiﬁcant
effect at 3, 6, or 12 months. However, mice that are treated
with daidzein during the prenatal period have lower femur
and lumbar spine BMD  than controls at 4 months of age
[21]. Endogenous hormone status and the age at BMD  mea-
surement may  affect experimental outcomes. The age at
which BMD  is most altered needs to be determined to fully
understand how bone mineral accumulation is affected by
prenatal or postnatal exposure to isoﬂavones. Bone qualityorts 2 (2015) 429–436
is also important for assessing bone development. Further
studies are required to conﬁrm the effects of daidzein on
bone development, such as measurement of biomechanical
strength and bone microarchitecture.
In male rats in the Dz-S and Dz-L groups, mean serum
osteocalcin concentrations on PND 22 were signiﬁcantly
lower than those in the Control group, but there was no
difference in female rats among the groups. These sex-
speciﬁc ﬁndings are consistent with those of previous
studies using a mouse model in which exposure to daidzein
(2 mg/kg body weight/day) from PNDs 1 to 5 improved
BMD [8] and microarchitecture in the femur of female mice
at 4 months of age, but it had minimal effects on bone
development in male mice [9]. Reports on men  with admin-
istration of aromatase and/like compounds have shown
that estrogen is crucial for bone growth and development
[22–24]. Estrogen withdrawal prevents epiphyseal fusion,
which stops bones from lengthening, up-regulates bone
resorption, and decreases BMD  [25]. Therefore, exposure
to estrogen-like compounds is crucial for healthy skele-
tal development in male mammals. In our study, daidzein
showed different effects on bone metabolism in female
rats compared with male rats. The reason for this ﬁnding
may  be because of the difference in types of sex hormones
[11]. Additionally, the change in BMD  in male rats on PND
77 observed in our study may  have occurred as a conse-
quence of programming effects in the fetal period. “The
concept of programming” is that a stimulus or insult during
a critical or sensitive period of development can have long-
term or lifetime effects on an organism [26]. Therefore,
hormonal signals operating during critical windows have
numerous programming effects. Estrogen-signaling path-
ways and modes of epigenetic programming have provided
some insight into the potential mechanism of action. By
binding and activating nuclear receptors, isoﬂavones may
interfere with hormonal signaling and/or the production of
enzymes and transcription factors [27,28]. During devel-
opment, such as fetal and/or perinatal periods, endocrine
hormones and enzymes can alter epigenetic regulation
that controls gene transcription [29]. It is speculated that
exposure to daidzein during the fetal period has induced
irreversible effects on bone metabolism in this study. Fur-
ther studies are required to conﬁrm the effects of perinatal
and peripubertal exposure to daidzein on bone develop-
ment, as well as to determine the underlying mechanism.
Safety is an important issue to consider when extrap-
olating these ﬁndings to isoﬂavone supplements or
soy-based infant formulas. We  investigated the effect of
daidzein on safety in addition to bone metabolism. We
found no marked differences in the outcome of pregnancy,
including the number of pups per litter, the sex ratio,
and birth weight. Our ﬁndings are consistent with those
of Ward et al. [9] who  reported that no effects on those
parameters were observed in exposure of pregnant mice to
genistein (3.75 mg/day) and/or daidzein (3.75 mg/day) sub-
cutaneously. Consequently, exposure of dams to daidzein
does not appear to have a remarkable effect on pregnancy
outcomes.
In our study, perinatal or peripubertal exposure to
daidzein did not affect body weight in female rats. How-
ever, peripubertal exposure to daidzein in the Dz-L group
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Fig. 3. Daidzein and equol concentrations in the stomach contents of suckling pups of dams that were fed a control diet or diet containing 0.5 g daidzein/kg
during pregnancy and lactation. Data are shown for PND 14. All values are means ± SEM (n = 6–9). Values that do not share the same superscript letters
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tre  signiﬁcantly different from each other (p < 0.05). Data were analyzed u
est.  Control group: rats were fed a control diet; Dz-S group: rats were fed
ats  were fed a daidzein diet (0.5 g daidzein/kg) during pregnancy, lactati
ncreased body weight in male rats on PND 35 compared
ith the Control and Dz-S groups (Table 1). There was no
igniﬁcant difference in male offspring body weight among
he groups on PND 77 (Table 1). In contrast to our ﬁnd-
ngs, Ronis et al. [30] showed that male rats exposed to
ietary isoﬂavones (80 mg/kg body weight/day) from PNDs
5 to 33 had reduced body weight at PND 33. In the present
tudy, the daidzein dose for offspring in the Dz-S and Dz-
 groups was calculated as approximately 51 mg/kg body
eight/day, which was lower than that in the study by
onis et al. [30]. Although a large number of studies have
hown that exposure to isoﬂavones during the prenatal
nd/or postnatal period inﬂuence growth, the results are
nconsistent.
In our study, the sex organ weights and AGD in male
nd female rats exposed to daidzein during the perina-
al or peripubertal periods did not change with treatment
Table 2). AGD is used as a measure of endocrine disruption.
 longer AGD at earlier onset of puberty has been observed
n female and male mice that were exposed to estrogen
31]. Our study indicated that exposure to daidzein dur-
ng the perinatal period or during the perinatal period and
fter weaning might not affect parameters of endocrine
isruption.
In our study, pregnant rats in the Dz-S and Dz-L
roups were fed approximately 50 mg  daidzein/kg body
eight/day (approximately 15 mg/day), and daidzein and
quol were detected in the stomach contents of suckling
ups (Fig. 3). Although daidzein is transferred from lac-
ating mothers to suckling pups [15], our results suggest
hat equol is also transferred from mothers to suckling pups
ia the breast milk of dams that are fed a diet containing
aidzein. Moreover, a similar transfer from mother to fetus
as been reported in rats and humans [15–17]. Daidzein
s rapidly transferred from the maternal circulation to the
etus, and elevated serum daidzein levels are present in rat
etuses from mothers that were fed isoﬂavones [15–17,32].
ne of the main metabolites of daidzein is equol, which is
hought to be the most potent modiﬁer of the effects ofe-way ANOVA. Differences between the groups were assessed by Tukey’s
ein diet (0.5 g daidzein/kg) during pregnancy and lactation; Dz-L group:
post-weaning.
isoﬂavones. Equol might mediate the effects of daidzein in
sex organ development and bone metabolism in rat fetuses
and offspring.
In our study, serum daidzein and equol concentrations
in offspring on PNDs 22, 35, and 77 were detected. A
previous study showed that circulating daidzein levels in
rats on PND 21 were similar to those in human infants
(1.16 ± 0.09 mol/L) who were fed a soy protein-based for-
mula [32]. Serum daidzein concentrations in rat offspring
on PNDs 35 and 77 in our study are several times higher
than those in Asian people [33,34]. The dose of isoﬂavones
that was  administered in the study was  much higher than
those from ordinary soy products. However, the dose of
soy isoﬂavones used in this study could be obtained by
isoﬂavones supplements. Our results suggest that exces-
sive intake of isoﬂavones during the prenatal and postnatal
periods should be carefully assessed in further studies. Fur-
ther investigation concerning the safety and efﬁcacy of soy
products fortiﬁed with isoﬂavones and extracted supple-
ments remains a research priority, particularly because of
their widespread availability and growing use.
5. Conclusions
In conclusion, we  assessed the safety and efﬁciency of
perinatal or peripubertal exposure to daidzein on bone and
reproductive organ development at early adulthood in rats.
Perinatal exposure to daidzein does not confer a positive
effect on BMD  in either male or female rats on PND 35. How-
ever, peripubertal exposure to daidzein protects against a
decline in BMD  in male and female rats on PND 35. Perinatal
exposure to daidzein leads to reduced femoral BMD  in male
rats, but not female rats, on PND 77. Therefore, the effects
of daidzein on bone metabolism during development may
depend on the timing of exposure and sex. Exposure to
daidzein during the perinatal or peripubertal period does
not have serious adverse effects on sexual development of
offspring. Further investigations should assess the mecha-
nisms underlying these responses of bone metabolism to
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